Clinical Trial Update: Combining Furmonertinib With Local Therapy for Inoperable Early-stage Lung Cancer: A Phase II Trial [Phase 2]

View source ↗

Summary

A Phase II study is exploring adding furmonertinib to local therapy for patients with inoperable, early-stage non-small cell lung cancer. The study status is NO…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Furmonertinib (furmonertinib)

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: NOT_YET_RECRUITING